Equity Field Notes from temporal sources

[DanWebzster]

GNBT Ii-key vaccine platform focues on viral proteins involved in receptor binding and infection.

A significant problem with most Covid vaccines in development is that they encode a SARS-Cov2 spike protein that prompts generation of antibodies, the majority of which are non-neutralizing.

Non-neutralizing antibodies simply stick to the virus w/o hampering its infectivity. This is because the vaccines are encoded for the whole spike rather than the relative epitopes on the spike involved with receptor bind and infection.

GNBT Ii-key platform's other major advantage is that it can design vaccines that preferentially stimulate Helper T-cells as opposed to regulatory T-cells which suppress immune response.

Also, unlike RNA vaccines, Ii-key vaccines do not require shipping at ultra-low temperature.

GNBT has signed a MOU with Bintai Kinden for exclusive rights to vaccinate against Covid in Malaysia. The deal would:
1) provide a $2.5M advance
2) provide $17.5M on approval
3) pay a royalty of $3-4.5 per dose.

GNBT is also negotiating with a Chinese concern.